897-15-4 Usage
Description
DOTHIEPIN HCL, also known as Dothiepin Hydrochloride, is a tricyclic antidepressant that belongs to the class of drugs known as monoamine reuptake inhibitors. It works by increasing the levels of neurotransmitters such as serotonin and norepinephrine in the brain, which helps to alleviate symptoms of depression and anxiety.
Uses
Used in Pharmaceutical Industry:
DOTHIEPIN HCL is used as a tricyclic antidepressant for the treatment of depression and anxiety disorders. It is effective in managing symptoms such as low mood, lack of energy, and feelings of hopelessness associated with depression. Additionally, it can also be used to treat other mental health conditions, such as obsessive-compulsive disorder and panic disorder.
Used in Mental Health Treatment:
DOTHIEPIN HCL is used as a monoamine reuptake inhibitor for the treatment of mental health disorders. It helps to increase the levels of neurotransmitters in the brain, which can improve mood, reduce anxiety, and promote a sense of well-being. This makes it a valuable tool in the management of various mental health conditions, including depression, anxiety, and other mood disorders.
Drug interactions
Potentially hazardous interactions with other drugsAlcohol: increased sedative effect.Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with
opioids.Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
dronedarone, flecainide or propafenone - avoid with
dronedarone.Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and possibly
delamanid and telithromycin - avoid with
moxifloxacin.Anticoagulants: may alter anticoagulant effect of
coumarins.Antidepressants: enhanced CNS excitation and
hypertension with MAOIs and moclobemide -
avoid; concentration possibly increased with SSRIs;
risk of ventricular arrhythmias with citalopram
and escitalopram - avoid; possible increased risk of
convulsions with vortioxetine.Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
phenobarbital and possibly fosphenytoin, phenytoin
and primidone.Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.Antipsychotics: increased risk of ventricular
arrhythmias especially with droperidol, fluphenazine,
haloperidol, pimozide, risperidone, sulpiride and
zuclopenthixol - avoid; increased antimuscarinic
effects with clozapine and phenothiazines;
concentration increased by antipsychoticsAntivirals: increased risk of ventricular arrhythmias
with saquinavir - avoid; concentration possibly
increased with ritonavir.Atomoxetine: increased risk of ventricular
arrhythmias and possibly convulsions.Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.Clonidine: tricyclics antagonise hypotensive
effect; increased risk of hypertension on clonidine
withdrawal.Dapoxetine: possible increased risk of serotonergic
effects - avoidDopaminergics: avoid use with entacapone; CNS
toxicity reported with selegiline and rasagiline.
Metabolism
Dosulepin hydrochloride is readily absorbed from the
gastrointestinal tract, and extensively demethylated by
first-pass metabolism in the liver to its primary active
metabolite, desmethyldothiepin (also termed northiaden).
Paths of metabolism also include S-oxidation.
Dosulepin is excreted in the urine, mainly in the form
of its metabolites; small amounts are also excreted in
the faeces. Elimination half-lives of about 14-24 and
23-46 hours have been reported for dosulepin and its
metabolites, respectively.
Dose in renal impairment GFR (mL/min)
20-50 Dose as in normal renal function.
10-20 Start with small dose and titrate
according to response.
<10 Start with small dose and titrate
according to response.
Dose in patients undergoing renal
replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/
min.
HD Not dialysed. Dose as in GFR<10 mL/
min.
HDF/High flux Unknown dialysability. Dose as in
GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in
GFR=10-20 mL/min.
Important drug interactions
Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with
opioids.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
dronedarone, flecainide or propafenone - avoid with
dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and possibly
delamanid and telithromycin - avoid with
moxifloxacin.
Anticoagulants: may alter anticoagulant effect of
coumarins.
Antidepressants: enhanced CNS excitation and
hypertension with MAOIs and moclobemide -
avoid; concentration possibly increased with SSRIs;
risk of ventricular arrhythmias with citalopram
and escitalopram - avoid; possible increased risk of
convulsions with vortioxetine.
Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
phenobarbital and possibly fosphenytoin, phenytoin
and primidone.
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with
Check Digit Verification of cas no
The CAS Registry Mumber 897-15-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 8,9 and 7 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 897-15:
(5*8)+(4*9)+(3*7)+(2*1)+(1*5)=104
104 % 10 = 4
So 897-15-4 is a valid CAS Registry Number.
InChI:InChI=1/C19H21NS.ClH/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19;/h3-6,8-12H,7,13-14H2,1-2H3;1H
897-15-4Relevant articles and documents
DOTHIEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS
-
Page/Page column 20-21, (2010/11/29)
The invention relates to dothiepin, metabolites of dothiepin, isomers of the same, and pharmaceutically-acceptable salts and prodrugs of the same; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.